ICMR has fast-tracked the project and selected a dozen institutes for clinical trials of the indigenous COVID-19 vaccine (BBV152 COVID vaccine).
In phase 0 of a clinical trial, investigators do tests with less number of people, usually fewer than 15.
The company has revealed that human clinical trials will begin across the country this month itself.
Zydus Cadila's vaccine "ZyCoV-D" has received permission to initiate phase I and II of human clinical trials in India. "The vaccine is being derived from a strain of SARS-CoV-2 isolated by ICMR-National Institute of Virology, Pune. ICMR and BBIL are jointly working for the pre-clinical as well as clinical development of this vaccine", the ICMR said in a letter to the institutes.
Out of a total of 140 companies across the world, seven Indian companies are also working on vaccine development against COVID-19.
Yet one of her colleagues, John Bell, Regius Professor of Medicine at Oxford University, said Britain should make preparations for the worst case scenario, namely that no vaccine would be ready by winter.
Trump campaign rallies to start up again in next two weeks
The Trump campaign, however, reports it still has plenty sitting in the bank, with $295 million cash on hand. Biden also slammed President Trump and his administration over the handling of the coronavirus pandemic.
The human trials began in Wuzhi County, central China's Henan Province on April 12. There are 6 phases of clinical trials. "This is going at a speed no other vaccine has ever gone".
Phase III usually involves up to 3,000 participants.
Speaking at a parliamentary hearing on Wednesday afternoon, Gilbert reportedly said: "We're very happy that we're seeing the right sort of immune response that will give protection, and not the wrong sort".
United States vaccine maker Inovio says "94% of people in the Phase 1 trial demonstrated overall immune responses by six weeks after receiving two doses of the vaccine INO-4800 and by eight weeks, the vaccine regimen was found to be safe and well-tolerated with no serious reactions", according to a CNN report.
There were no safety concerns for the vaccine candidate in repeat dose toxicology studies, Zydus said.